CD19-directed CAR T-cell therapies are approved for a variety of B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL: tisa-cel, brexu-cel, obe-cel), diffuse large B-cell lymphoma (DLBCL: tisa-cel, axi-cel, liso-cel), mantle cell lymphoma (MCL: brexu-cel, liso-cel), follicular lymphoma (FL: tisa-cel, axi-cel, liso-cel), and chronic lymphocytic leukemia (CLL: liso-cel only). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.